Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of adjuvant fluoropyrimidine with or without oxaliplatin therapy in older adults with mismatch repair deficient stage III colorectal cancer.
Authors
Jerod J Sears
Washington University School of Medicine, St. Louis, MO;
Jerod J Sears , Zishuo Ian Hu , Jingxia Liu , Samuel Ballentine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 112)
DOI
10.1200/JCO.2023.41.4_suppl.112
Abstract #
112
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of t-CORE0901.
First Author: Makio Gamoh
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Changes in prescribing patterns in stage III colon cancer (CC) since the IDEA collaboration.
First Author: Daniel Walden
Poster
2017 ASCO Annual Meeting
Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance.
First Author: In Gyu Hwang
Poster
2012 Gastrointestinal Cancers Symposium
Comparative effectiveness of treatment options in elderly patients with colon cancer receiving adjuvant chemotherapy.
First Author: Sacha Satram-Hoang